Recent Analysis on Allergic Asthma Therapeutics Market 2020 – 2027 Top Trends, Business Opportunity, and Growth Strategy

SEATTLE, May 04, 2021, (PHARMIWEB) —

Global Allergic Asthma Therapeutics Market, by Drug Type (Corticosteroids, Bronchodilators, Leukotriene modifiers, Immunotherapy, Biologics, and Others), by Route of Administration (Oral, Inhaled, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued over US$ 6,704.8 million in 2020 and is expected to register a CAGR around 2.93% over the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

In June 2017, Teva Pharmaceuticals Industries Ltd. received the U.S. FDA licensed for its three products; ArmonAir, RespiClick, and AirDuo RespiClick. There are asthma inhalers for adults and adolescent patients, who suffer from asthma. Patients in the United States will get ArmonAir and AirDuo with a prescription. ArmonAir’s approved strengths such as 232 mcg, 55 mcg, and 113 mcg, while AirDuo’s approved strengths are 232/14 mcg, 55/14 mcg, and 113/14 mcg, and 55/14 mcg, administered twice daily.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/4019

Moreover, in October 2018, the FDA approved Regeneron Pharmaceuticals, Inc. and Sanofi’s Dupixent (dupilumab) as an alternative preventive treatment for patients with moderate-to-severe asthma.

Impact of Coronavirus (Covid-19) Pandemic

The unexpected global outbreak of COVID-19 has had a major effect on the allergic asthma therapeutics industry. Despite the fact that the risk of COVID-19 affecting asthma patients is higher, authorities are taking every precaution to make vital solutions (ventilators, inhalers) accessible to patients. The stock of respiratory drugs has not been damaged as a result of the pandemic.

COVID-19’s effect and expected improvements in the industry’s future outlook will be included in the detailed version of the study, which will take into account social, economic, political, and technical parameters.

Key players in the market are investing towards research and development initiatives, concentrating on geographical expansions, and joint ventures to strong their position in the global allergic asthma therapeutics market. For instance, in May 2019, Singapore-based biopharma company, ASLAN Pharmaceuticals, revised its license agreement with CSL Limited (CSL) to have full global rights for developing, manufacturing, and commercializing ASLAN004 in all indications. ASLAN004 assists in the inducing of allergic asthma symptoms such as wheezing, shortness of breath, coughing, and disease exacerbations.

The global allergic asthma therapeutics market is estimated to register a CAGR around 2.9%over the forecast period (2020-2027) due to the increasing number of respiratory disorders, and strategic partnerships and joint ventures on the basis of market players.

With their novel single and combination asthma treatment drugs, pipeline products from AstraZeneca, Sanofi, GSK, AB Science, Mundipharma, Shanghai Biomabs Pharmaceutical Co., Ltd., and Chiesi Farmaceutici, among others, will transcend the industry scenario in the foreseeable future.

Key players are dominating in the global allergic asthma therapeutics market such as Baxalta Incorporated, Aslan Pharmaceuticals Pte. Ltd., Chiesi Farmaceutici SpA, Axikin Pharmaceuticals, Fountain Biopharma Inc., CSL Limited, Circassia Pharmaceuticals Plc, GlaxoSmithKline Plc, Hydra Biosciences, Infinity Pharmaceuticals, Kineta, Mabtech Limited, Marinomed Biotechnologie Gmb, NeoPharm Co., Panacea Biotec Limited, Oxagen Limited and Mycenax Biotech Inc.

Buy This Complete A Business Report: https://www.coherentmarketinsights.com/insight/buy-now/4019

Detailed Segmentation:

By Drug Type:

• • Corticosteroids
  • Bronchodilators
  • Leukotriene modifiers
  • Immunotherapy
  • Biologics
  • Others

By Route of Administration:

• • Oral
  • Inhaled
  • Others

View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/allergic-asthma-therapeutics-market-3289

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contacts US:

Mr. Shah
Coherent Market Insights,
1001 4th Ave,
#3200 Seattle, WA 98154, U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
Email: sales@coherentmarketinsights.com